Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling.

Literature DB >> 8852571

Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling.

F Falcini¹, S Trapani, M Ermini, M L Brandi.

Abstract

The purpose of the investigation was to test the use of alendronate in the therapy of children affected by chronic rheumatic diseases and symptomatic drug-induced osteoporosis. Two courses of alendronate were intravenously administered to four girls with vertebral fractures that were glucocorticoid induced. Improvement of back pain and bone mineral density increase evaluated by DXA and conventional spine X-rays were observed. Our study supports the ABD-induced improvement of the negative effects of long-term therapy on bone mineral density in children with chronic rheumatic diseases.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1996 PMID： 8852571 DOI： 10.1007/bf02526882

Source DB: PubMed Journal: Calcif Tissue Int ISSN： 0171-967X Impact factor: 4.333

18 in total

Review 1. Glucocorticoid-induced osteoporosis: pathogenesis and management.

Authors: B P Lukert; L G Raisz
Journal: Ann Intern Med Date: 1990-03-01 Impact factor: 25.391

Review 2. Bisphosphonates and osteoporosis.

Authors: O H Sørensen; T Storm; G Thamsborg; H A Sørensen; G Kollerup; T Steiniche; F Melsen; H K Genant
Journal: Osteoporos Int Date: 1993 Impact factor: 4.507

3. Prospective use of bisphosphonates in osteoporosis.

Authors: H Fleisch
Journal: J Clin Endocrinol Metab Date: 1993-06 Impact factor: 5.958

4. Bisphosphonates: pharmacology.

Authors: H Fleisch
Journal: Semin Arthritis Rheum Date: 1994-02 Impact factor: 5.532

Review 5. Treatment of osteoporosis with bisphosphonates.

Authors: N B Watts
Journal: Rheum Dis Clin North Am Date: 1994-08 Impact factor: 2.670

Review 6. Effects of glucocorticoid treatment on the ultrastructure of cartilage and bone.

Authors: E Bonucci; L C Dearden; H D Mosier
Journal: Adv Exp Med Biol Date: 1984 Impact factor: 2.622

7. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.

Authors: P Sambrook; J Birmingham; P Kelly; S Kempler; T Nguyen; N Pocock; J Eisman
Journal: N Engl J Med Date: 1993-06-17 Impact factor: 91.245

Review 8. Corticosteroid-induced osteoporosis.

Authors: J D Adachi; W G Bensen; A B Hodsman
Journal: Semin Arthritis Rheum Date: 1993-06 Impact factor: 5.532

9. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis.

Authors: M Passeri; M C Baroni; M Pedrazzoni; G Pioli; M Barbagallo; D Costi; M Biondi; G Girasole; B Arlunno; E Palummeri
Journal: Bone Miner Date: 1991-12

10. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

Authors: I R Reid; A R King; C J Alexander; H K Ibbertson
Journal: Lancet Date: 1988-01-23 Impact factor: 79.321

8 in total

Review 1. Juvenile dermatomyositis: recognition and treatment.

Authors: Ann M Reed; Maricarmen Lopez
Journal: Paediatr Drugs Date: 2002 Impact factor: 3.022

Review 2. Osteoporosis.

Authors: R Cimaz; M Biggioggero
Journal: Curr Rheumatol Rep Date: 2001-10 Impact factor: 4.592

3. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.

Authors: L I Plotkin; R S Weinstein; A M Parfitt; P K Roberson; S C Manolagas; T Bellido
Journal: J Clin Invest Date: 1999-11 Impact factor: 14.808

Review 4. Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis.

Authors: J Thornton; D M Ashcroft; M Z Mughal; R A Elliott; T W O'Neill; D Symmons
Journal: Arch Dis Child Date: 2006-05-11 Impact factor: 3.791